The Canadian government has granted permission to a startup for exporting psychedelic substances to Australia for medicinal use. The entrusted startup, Optimi Health Corp., is responsible for shipping pills infused with psilocybin, an extract from magic mushrooms, and MDMA, as approved by the health department.
The growing demand goes beyond the local magic mushrooms Ontario. Other countries are following Canada’s lead, commencing exploration and legalization of serotogenic compounds for medical applications.
Confidently buy psychedelics online in Canada and tap into your innate potential through trustworthy sources.
[toc]Main Takeaways:
- Vancouver-based startup Optimi Health has received a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in the treatment of chronic depression.
- The treatment consists of three sessions spanning five to eight weeks, with each session approximately eight hours long.
Rise of Psilocybin Capsules in Canada
Optimi, a fledgling Vancouver-based company, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and gain an early-market edge.
Seven firms have exported psilocybin, MDMA, or both, but only for clinical trial objectives. A spokesperson from Canada’s health department couldn’t confirm if these exports were for regular patient use and chose not to reveal the companies due to privacy concerns.
This accomplishment places Optimi in a unique group of international suppliers, as the current market tends more towards clinical rather than recreational use.
What’s in the Pill?
While the company hasn’t disclosed the specific type of mushroom used in the pill, they do utilize various strains such as Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, with a population of approximately 3,000 people, is situated three hours east of Vancouver.
Australia’s Relationship with Psychedelic Mushrooms
Statistically, one in every five Australians aged between 16 and 85 could potentially experience a mental health condition. Post-traumatic stress disorder (PTSD) may impact 11% of Australians at some point, and anxiety disorders are common, affecting about 17% of the population.
A multitude of methods are available for treating mental disorders, but not every method is effective for every individual. Those who do not respond to certain treatments may find it difficult to find a suitable approach, thus increasing their susceptibility.
Understanding the Process
Australia is leading the way in the use of psilocybin, allowing licensed psychiatrists to apply this controlled substance in treating PTSD and depression resistant to traditional treatments.
Surprisingly, in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and shrooms for therapeutic purposes. The TGA affirmed that these substances are safe when used in a medically regulated environment for patients with severe mental disorders.
This shift has been groundbreaking for many mental health professionals and researchers. The administration of these substances will be strictly monitored; it’s not as simple as taking a pill and walking away.
The treatment regimen typically consists of three sessions spread over five to eight weeks. Each session lasts approximately eight hours, with the therapist staying with the patient throughout.
Canada’s Role in Psilocybin Research
Canada has positioned itself as a leading center for psilocybin research, greatly advancing our understanding of this compound. Health Canada, in conjunction with various institutions, is spearheading the investigation of psilocybin’s therapeutic potential for various mental health conditions.
Research institutions no longer need to label these substances as illegal or rely on unauthorized dispensaries or mushroom shops. The government now permits certain institutions to grow shrooms for research purposes.
The increased accessibility to substances formerly deemed harmful enables researchers to deepen their understanding of their potential benefits for many people.
A Cyclic Patterns
The potential for addressing mental health and substance abuse problems, including alcoholism, was first identified in this field during the 1950s. Pioneers of this early research included English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer, who conducted significant studies at the Saskatchewan Mental Hospital in Weyburn. The facility saw significant advancements under the leadership of then-premier Tommy Douglas, who gave the medical community considerable freedom to explore their hypotheses.
Dr. Osmond and Dr. Hoffer pursued investigations using LSD, mescaline, and peyote as potential alternatives to the harsh methods of electroshock and lobotomy. Their research took unexpected turns, leading them to advocate for the experimental use of these substances by doctors, nurses, and support staff.
Research at Canadian Health Institutes
The Canadian Institutes of Health Research, through the Institute of Neurosciences, Mental Health and Addiction, is funding three clinical trials to study the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress related to end-of-life in advanced-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Processes supporting psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a deeper understanding of the advantages of regulated substances. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Canadian government, has made this possible.
Additional Research on Psychedelics
Psychiatrists in Vancouver have begun a phase III clinical trial of MDMA, commonly known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The treatment includes three eight-hour MDMA sessions, scheduled a month apart, and nine 90-minute sessions without the drug. This trial is considered historically significant as it marks the first clinical evaluation of an illicit substance.
Psilocybin is a psychedelic compound that occurs naturally in certain types of mushrooms. Once ingested, it metabolizes into psilocin, which subsequently activates serotonin 5-HT2a receptors. These receptors are found on the cortical pyramidal cells in the brain, functioning as primary processing sites.
Currently, researchers are examining the substance’s ability to aid in the treatment of depression, anxiety, addiction, and end-of-life distress. These therapeutic benefits are thought to stem from the introspective and spiritually enlightening effects of the compound.
Why is it Effective in Treating Depression, PTSD, and Other Conditions?
The active ingredient in psilocybin influences several areas of the brain, making it potentially useful for a range of mental health conditions. In Canada and Australia, many patients have already undergone treatment using this therapy. The results reported so far are promising, with minor side effects such as temporary anxiety and elevated blood pressure.
The Impact on Neurobiology
- Activation of Serotonin Receptors: Psilocybin serves as a partial agonist at serotonin receptors, especially the 5-HT2A subtype. This is essential for mood regulation and emotional processing.
- Modulation of the Default Mode Network (DMN): Psilocybin reduces activity in the DMN, promoting introspection, reducing rigid thinking, and fostering emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of psilocybin stem from its impact on the prefrontal and limbic regions of the brain, including the amygdala. In depressed individuals, there is often a decreased response to emotional stimuli. Psilocybin enhances the response to positive emotional stimuli in the right amygdala and mitigates or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Impacts:
- Creation of Positive Mood States: Psilocybin promotes feelings of euphoria, interconnectedness, and emotional openness during and following the experience.
- Enhanced Emotional Processing: The psychedelic experience can allow individuals to confront and process deep-seated emotions, traumatic memories, or existential anxieties in a supportive setting.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College London suggests that psilocybin can provide profound spiritual and existential insights, which may contribute to lasting improvements in psychological well-being.
What Products Are Available at Your Local Magic Mushroom Stores?
Interested in how this substance might impact your mental health? Explore various magic mushroom retailers to find a product that suits your preferences.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, stimulates creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and improves overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and focus. Features a strong mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy enhancements |
International Acceptance of Psilocybin
Canada isn’t the only country acknowledging the potential of magic mushrooms for mental health treatment. Countries like Australia also endorse the use of these substances to manage conditions such as depression and PTSD. They are procuring top-quality psychedelic capsules from trusted sources. With the right supervision, patients can significantly improve their quality of life. Magic Mushies Canada, a magic mushroom supplier, offers a variety of products, ranging from capsules to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA compare?
Both psilocybin and MDMA have therapeutic value in enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA engenders empathy and is instrumental in PTSD therapy. It demonstrates potential in improving emotional processing and
Despite being classified as a controlled substance, it has shown promising therapeutic results.
Is this treatment option accessible to all Australians?
In Australia, not everyone qualifies for this treatment. Individuals must first undergo an evaluation to assess their suitability for the substance use, taking into account factors such as pre-existing heart conditions and history of psychosis. This treatment is only offered to those patients who have not responded to conventional treatments for conditions like depression, anxiety, or PTSD.
What are the implications of Canada exporting mushrooms?
Canada is strategically positioning itself to lead the psychedelics market, mirroring its approach with cannabis. This could establish a path for more companies to produce top-quality products. As a result, Canada could become a leading player in the hallucinogen market, strengthening its economy and increasing access to treatments in other countries. It would also discourage these countries from obtaining their hallucinogens from unauthorized dispensaries or suppliers, ensuring safety.
Articles That Might Interest You:
